Monopar and northstar partner with aragen for testing of novel potential therapeutic for severe covid-19

Wilmette, ill. and beloit, wis. and morgan hill, calif., aug. 19, 2020 (globe newswire) -- monopar therapeutics inc. (nasdaq: mnpr) (wilmette, il) and northstar medical radioisotopes, llc (beloit, wi), who are collaborating on the development of urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uprits) for the potential treatment of patients with severe covid-19, today announced a partnership with aragen bioscience, inc. (morgan hill, ca),  a leading contract research organization focused on accelerating preclinical biologics product development. aragen will perform studies aimed at selecting a lead candidate uprit to advance into ind-enabling development for severe covid-19.
MNPR Ratings Summary
MNPR Quant Ranking